GERN
NASD Geron Corporation$1.20 ↑ +0.00 (+0.00%) Trading Up from the previous close of $1.20, $0.02 below the day’s high of $1.22
- YTD change
- -9.09%
- vs 20-day SMA
- -9.77%
- vs 200-day SMA
- -17.00%
Price ranges
Price & Performance
-0.55 (-31.43%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 82.8% away from all-time highs of $6.99
- GERN is down 9% since the beginning of the year
- GERN is down 13% over the past 12 months
- GERN is down 25% over the past 1 month
- 13% of all GERN investors are betting against GERN
GERN reads poor: price sits below both the 20- and 200-day averages, the 12-month move is -11.1%.
- Previous minute
- +$0.00
- Last hour
- -$0.00
- Last 5 days
- -4.76%
- vs 8-day SMA
- -4.00%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.